Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 282 | -7.7 | 73.4 | 2.2 | -7.3 | — |
| Depreciation and amortization | 4.6 | 4.2 | 4.8 | 4.0 | 4.3 | — |
| Capital expenditure | — | — | -3.4 | -0.1 | -4.3 | -0.7 |
| Investing cash flow | -2.9 | -6.8 | -3.4 | -0.1 | -4.3 | — |
| Financing cash flow | -46.1 | -36.8 | 8.5 | 38.9 | 7.0 | — |
| Share repurchases | -51.6 | -51.9 | 0.0 | 0.0 | 0.0 | — |
| Debt issued | — | — | 0.0 | — | — | — |
| Debt repaid | -8.1 | -8.6 | -6.8 | -6.6 | -5.5 | — |
| Effect of exchange rates | 6.7 | 8.1 | -1.6 | 4.1 | -19.2 | — |
| Net change in cash | 233 | -51.3 | 78.5 | 41.0 | -4.7 | — |
| Free cash flow | 271 | -7.7 | 70.0 | 2.1 | -12.4 | — |